1 / 6

HPS. Lancet . 2003;361:2005-16. Gæde P et al. N Engl J Med . 2003;348:383-93.

Recent statin trials: Reduction in primary outcome in patients with diabetes. HPS. Steno-2. 0. 10. 22. 20. Relative risk reduction (%). P < 0.0001. 30. 40. 53. 50. P = 0.007. 60. HPS: major coronary event, stroke, or revascularization

kare
Télécharger la présentation

HPS. Lancet . 2003;361:2005-16. Gæde P et al. N Engl J Med . 2003;348:383-93.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Recent statin trials: Reduction in primaryoutcome in patients with diabetes HPS Steno-2 0 10 22 20 Relativeriskreduction(%) P < 0.0001 30 40 53 50 P = 0.007 60 HPS: major coronary event, stroke, or revascularization Steno-2: CV death, nonfatal MI, CABG, PCI, nonfatal stroke,amputation for ischemia, or vascular surgery for PAD HPS. Lancet. 2003;361:2005-16. Gæde P et al. N Engl J Med. 2003;348:383-93.

  2. CARDS: Collaborative AtoRvastatin Diabetes Study design High-risk patients with type 2 diabetes (N = 2838) Atorvastatin 10 mg Placebo Randomization completeJune 2001 Early termination June 2003 ResultsannouncedJune 2004 Plannedcompletion2005 Primary outcome: Composite of major coronary events, revascularizations, unstable angina, resuscitated cardiac arrest, and stroke Colhoun HM et al. Diabet Med. 2002;19:201-11.

  3. CARDS: Treatment effects on lipids Total-CAverage difference 26%1.4 mmol/L (54 mg/dL) LDL-CAverage difference 40%1.2 mmol/L (46 mg/dL) 6 4 3 4 2 mmol/L 2 1 P < 0.0001 P < 0.0001 0 0 0 1 2 3 4 4.5 0 1 2 3 4 4.5 Years Years Placebo Atorvastatin Colhoun HM et al. Lancet. 2004;364:685-96.

  4. 15 Relative risk reduction 37%95% CI, 17%–52% P = 0.001 Placebo127 events 10 Cumulativehazard(%) Atorvastatin83 events 5 0 0 1 2 3 4 4.75 Years Placebo 1410 1351 1306 1022 651 305 Atorvastatin 1428 1392 1361 1074 694 328 CARDS: 37% Reduction in primary outcome Colhoun HM et al. Lancet. 2004;364:685-96.

  5. CARDS: Consistent statin effects on components of primary outcome n (% randomized) Favorsatorvastatin Favorsplacebo Risk reduction (95% CI) Event Placebo Atorvastatin 37% (17–52)P = 0.001 Primary outcome 127 (9.0) 83 (5.8) Acute coronary events 77 (5.5) 51 (3.6) 36% (9–55) Coronaryrevascularization 34 (2.4) 24 (1.7) 31% (–16–59) Stroke 39 (2.8) 21 (1.5) 48% (11–69) 0.2 0.4 0.6 0.8 1.0 1.2 Hazard ratio Colhoun HM et al. Lancet. 2004;364:685-96.

  6. ACP recommendations for lipid management in patients with diabetes • Lipid-lowering therapy is indicated for secondary prevention in all patients with diabetes and known coronary artery disease • Statins are indicated for primary prevention of macrovascular complications in patients with diabetes and other CV risk factors • Once statin therapy is initiated, patients should receive at least moderate doses • Routine monitoring of liver function or muscle enzymes is not recommended for patients receiving statins, except in specific circumstances Snow V et al. Ann Intern Med. 2004;140:644-9.

More Related